Glycation & the RAGE axis: targeting signal transduction through DIAPH1
- PMID: 27967251
- PMCID: PMC5535775
- DOI: 10.1080/14789450.2017.1271719
Glycation & the RAGE axis: targeting signal transduction through DIAPH1
Abstract
The consequences of chronic disease are vast and unremitting; hence, understanding the pathogenic mechanisms mediating such disorders holds promise to identify therapeutics and diminish the consequences. The ligands of the receptor for advanced glycation end products (RAGE) accumulate in chronic diseases, particularly those characterized by inflammation and metabolic dysfunction. Although first discovered and reported as a receptor for advanced glycation end products (AGEs), the expansion of the repertoire of RAGE ligands implicates the receptor in diverse milieus, such as autoimmunity, chronic inflammation, obesity, diabetes, and neurodegeneration. Areas covered: This review summarizes current knowledge regarding the ligand families of RAGE and data from human subjects and animal models on the role of the RAGE axis in chronic diseases. The recent discovery that the cytoplasmic domain of RAGE binds to the formin homology 1 (FH1) domain, DIAPH1, and that this interaction is essential for RAGE ligand-stimulated signal transduction, is discussed. Finally, we review therapeutic opportunities targeting the RAGE axis as a means to mitigate chronic diseases. Expert commentary: With the aging of the population and the epidemic of cardiometabolic disease, therapeutic strategies to target molecular pathways that contribute to the sequelae of these chronic diseases are urgently needed. In this review, we propose that the ligand/RAGE axis and its signaling nexus is a key factor in the pathogenesis of chronic disease and that therapeutic interruption of this pathway may improve quality and duration of life.
Keywords: DIAPH1; Glycation; RAGE; diabetes; inflammation; neurodegeneration; obesity; receptor for AGE.
Conflict of interest statement
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Figures

Similar articles
-
The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.Expert Opin Ther Targets. 2016;20(4):431-46. doi: 10.1517/14728222.2016.1111873. Epub 2015 Nov 11. Expert Opin Ther Targets. 2016. PMID: 26558318 Free PMC article. Review.
-
The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system.Neurochem Int. 2019 Jun;126:154-164. doi: 10.1016/j.neuint.2019.03.012. Epub 2019 Mar 20. Neurochem Int. 2019. PMID: 30902646 Free PMC article. Review.
-
The RAGE/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease.Cardiovasc Res. 2024 Feb 17;119(18):2813-2824. doi: 10.1093/cvr/cvac175. Cardiovasc Res. 2024. PMID: 36448548 Free PMC article. Review.
-
Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling.Structure. 2016 Sep 6;24(9):1509-22. doi: 10.1016/j.str.2016.06.021. Epub 2016 Aug 11. Structure. 2016. PMID: 27524199 Free PMC article.
-
RAGE signaling antagonist suppresses mouse macrophage foam cell formation.Biochem Biophys Res Commun. 2021 May 28;555:74-80. doi: 10.1016/j.bbrc.2021.03.139. Epub 2021 Apr 1. Biochem Biophys Res Commun. 2021. PMID: 33813279
Cited by
-
Effects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice.Pharmacol Res Perspect. 2020 Aug;8(4):e00636. doi: 10.1002/prp2.636. Pharmacol Res Perspect. 2020. PMID: 32776498 Free PMC article.
-
Role of Receptor for Advanced Glycation End-Products in Endometrial Cancer: A Review.Cancers (Basel). 2024 Sep 19;16(18):3192. doi: 10.3390/cancers16183192. Cancers (Basel). 2024. PMID: 39335163 Free PMC article. Review.
-
22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage.Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):613-621. doi: 10.1161/ATVBAHA.117.307263. Epub 2017 Feb 9. Arterioscler Thromb Vasc Biol. 2017. PMID: 28183700 Free PMC article. Review.
-
Journey to a Receptor for Advanced Glycation End Products Connection in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: With Stops Along the Way in the Lung, Heart, Blood Vessels, and Adipose Tissue.Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):614-627. doi: 10.1161/ATVBAHA.120.315527. Epub 2020 Dec 17. Arterioscler Thromb Vasc Biol. 2021. PMID: 33327744 Free PMC article. Review.
-
Investigating the Inhibitory Effects of Paliperidone on RAGEs: Docking, DFT, MD Simulations, MMPBSA, MTT, Apoptosis, and Immunoblotting Studies.Int J Mol Sci. 2025 Jan 26;26(3):1060. doi: 10.3390/ijms26031060. Int J Mol Sci. 2025. PMID: 39940823 Free PMC article.
References
-
- Marinakis E, Bagkos G, Piperi C, Roussou P, Diamanti-Kandarakis E. Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention? Clin Chem Lab Med. 2014;52:189–200. - PubMed
-
- Gaens KH, Goossens GH, Niessen PM, et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol. 2014;34:1199–1208. This paper describes for the first time the differential expression of RAGE protein in obese and lean human subject adipose tissue. The authors showed that RAGE expression was higher in obese vs. lean human adipose tissue and localized to adipocytes, vascular and immune cells. This work links RAGE to the pathogenesis of obesity. - PubMed
-
- Juranek JK, Daffu GK, Wojtkiewicz J, Lacomis D, Kofler J, Schmidt AM. Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. Front Cell Neurosci. 2015;9:485. This paper reports that RAGE and its ligands are highly expressed in the spinal cord of human subjects affected with ALS compared to more basal expression in the normal spinal cord. These studies suggest that the ligands of RAGE are upregulated in chronic disease and lead to the hypothesis that RAGE might contribute to neuronal dysfunction and loss in ALS. - PMC - PubMed
-
- Malik P, Chaudhry N, Mittal R, Mukherjee TK. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim Biophys Acta. 2015;1850:1898–1904. - PubMed
-
- Nienhuis HL, Westra J, Smit AJ, Limburg PC, Kallenberg CG, Bijl M. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity. 2009;42:302–304. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous